ReviewActa pharmacologica Sinica2013
Disease modeling and drug screening for neurological diseases using human induced pluripotent stem cells.
Review in Acta pharmacologica Sinica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- SLC26A4 C.317C > A Variant: Functional Analysis and Patient-Derived Induced Pluripotent Stem Line Development.Molecular genetics & genomic medicine · 2025Article
- Apelin/APJ system: a novel promising target for anti-oxidative stress in stroke.Frontiers in pharmacology · 2024Review
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Engineering circuits of human iPSC-derived neurons and rat primary glia.Frontiers in neuroscience · 2023Article
- Mitochondrial genome mutations and neuronal dysfunction of induced pluripotent stem cells derived from patients with Alzheimer's disease.Cell proliferation · 2022Article
- Multidisciplinary Effort to Drive Precision-Medicine for the Future.Frontiers in digital health · 2022Article
- Article
- Nontraditional systems in aging research: an update.Cellular and molecular life sciences : CMLS · 2021Review
- Longitudinal Characterization of Transcriptomic, Functional, and Morphological Features in Human iPSC-Derived Neurons and Their Application to Investigate Translational Progranulin Disease Biology.Frontiers in aging neuroscience · 2020Article
- A transient reporter for editing enrichment (TREE) in human cells.Nucleic acids research · 2019Article
- A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons.Scientific reports · 2019Article
- Review
- The Roles of MicroRNAs in Stroke: Possible Therapeutic Targets.Cell transplantation · 2018Review
- Stem cells technology: a powerful tool behind new brain treatments.Drug delivery and translational research · 2018Review
- Neuroprotective Role of Agmatine in Neurological Diseases.Current neuropharmacology · 2018Review
- Induced pluripotent stem cell: A headway in reprogramming with promising approach in regenerative biology.Veterinary world · 2017Review
- Glia-neuron interactions in neurological diseases: Testing non-cell autonomy in a dish.Brain research · 2017Review
- Neuroprotective Effects of Stem Cells in Ischemic Stroke.Stem cells international · 2017Review
- Novel therapeutic approaches: Rett syndrome and human induced pluripotent stem cell technology.Stem cell investigation · 2017Review
- Wnt-YAP interactions in the neural fate of human pluripotent stem cells and the implications for neural organoid formation.Organogenesis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the general decline of pharmaceutical research productivity, there are concerns that many components of the drug discovery process need to be redesigned and optimized. For example, the human immortalized cell lines or animal primary cells commonly used in traditional drug screening may not faithfully recapitulate the pathological mechanisms of human diseases, leading to biases in assays, targets, or compounds that do not effectively address disease mechanisms. Recent advances in stem cell research, especially in the development of induced pluripotent stem cell (iPSC) technology, provide a new paradigm for drug screening by permitting the use of human cells with the same genetic makeup as the patients without the typical quantity constraints associated with patient primary cells. In this article, we will review the progress made to date on cellular disease models using human stem cells, with a focus on patient-specific iPSCs for neurological diseases. We will discuss the key challenges and the factors that associated with the success of using stem cell models for drug discovery through examples from monogenic diseases, diseases with various known genetic components, and complex diseases caused by a combination of genetic, environmental and other factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.